Cargando…

Romosozumab improves low bone mineral density in a postmenopausal woman undergoing chronic hemodialysis and treated with a calcium-sensing receptor agonist

Preventing osteoporotic fractures is an issue requiring urgent attention to reduce mortality. However, unlike chronic kidney disease-mineral and bone disorder (CKD-MBD), osteoporosis is inadequately addressed in patients undergoing chronic dialysis. In fact, little is known about the proper use of a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ogata, Masatomo, Ushimaru, Shu, Fujishima, Rie, Sumi, Hirofumi, Shiizaki, Kazuhiro, Tominaga, Naoto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685381/ https://www.ncbi.nlm.nih.gov/pubmed/36438716 http://dx.doi.org/10.1016/j.bonr.2022.101639

Ejemplares similares

Renal anemia with a relatively normal renal function in vasculitis-induced acute tubulointerstitial damage
por: Ogata, Masatomo, et al.
Publicado: (2023)

Bone responsiveness to parathyroid hormone is negatively associated with parathyroid hormone-lowering drug use in patients undergoing hemodialysis: a cross-sectional study
por: Tominaga, Naoto, et al.
Publicado: (2021)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

Impact of romosozumab on serum calcium concentration and factors predicting the fluctuations in calcium concentration upon romosozumab administration: A multicenter retrospective study
por: Inose, Hiroyuki, et al.
Publicado: (2022)

Romosozumab for osteoporosis
Publicado: (2021)

Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients
por: Shimizu, Tomohiro, et al.
Publicado: (2021)

Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada
por: Goeree, Ron, et al.
Publicado: (2022)

OR13-06 Romosozumab After Denosumab Improves Lumbar Spine Bone Mineral Density And Microarchitecture Greater Than Denosumab Continuation In Postmenopausal Women
por: Hong, Namki, et al.
Publicado: (2023)

Romosozumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2018)

Giant Simple Kidney Cyst Resulting in Leg Edema Due to Inferior Vena Cava Compression
por: Ogata, Masatomo, et al.
Publicado: (2023)

Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden
por: Söreskog, E., et al.
Publicado: (2021)

Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis
por: Jeong, Chaiho, et al.
Publicado: (2021)

Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild‐to‐Moderate Chronic Kidney Disease
por: Miller, Paul D, et al.
Publicado: (2022)

Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis
por: Jeong, Chaiho, et al.
Publicado: (2022)

Romosozumab and cardiovascular safety in Japan
por: Takeuchi, Yasuhiro
Publicado: (2021)

Effects of vitamin D deficiency and daily calcium intake on bone mineral density and osteoporosis in Korean postmenopausal woman
por: Chon, Seung Joo, et al.
Publicado: (2017)

Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals
por: Cosman, Felicia, et al.
Publicado: (2021)

Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis
por: Hu, Mingwei, et al.
Publicado: (2023)

Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study
por: Baek, Ki-Hyun, et al.
Publicado: (2021)

Romosozumab in osteoporosis: yesterday, today and tomorrow
por: Wu, Dong, et al.
Publicado: (2023)

How Much Calcium Does an Indian Postmenopausal Woman Need?
por: Meeta, Meeta
Publicado: (2022)

Biological and Clinical Effects of Calciprotein Particles on Chronic Kidney Disease-Mineral and Bone Disorder
por: Akiyama, Kenichi, et al.
Publicado: (2018)

Risk of falls in postmenopausal women treated with romosozumab: Preliminary indices from a meta-analysis of randomized, controlled trials
por: Möckel, Luis, et al.
Publicado: (2020)

The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study
por: Geusens, Piet, et al.
Publicado: (2019)

Profile of romosozumab and its potential in the management of osteoporosis
por: Lim, Sian Yik, et al.
Publicado: (2017)

Romosozumab and antiresorptive treatment: the importance of treatment sequence
por: Cosman, Felicia, et al.
Publicado: (2022)

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab
por: Kendler, D.L., et al.
Publicado: (2019)

Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study
por: Tominaga, A., et al.
Publicado: (2021)

Romosozumab versus Teriparatide for the Treatment of Postmenopausal Osteoporosis: A Systematic Review and Meta‐analysis through a Grade Analysis of Evidence
por: Tian, Aixian, et al.
Publicado: (2021)

Skeletal responses to romosozumab after 12 months of denosumab
por: McClung, Michael R., et al.
Publicado: (2021)

Romosozumab-aqqg in the Treatment of Osteoporosis in a Patient With Hypophosphatasia
por: Khanjee, Naveed, et al.
Publicado: (2022)

MON-378 Efficacy and Safety of Romosozumab vs Alendronate Is Similar Across Different Levels of Renal Function Among Postmenopausal Women with Osteoporosis
por: Miller, Paul, et al.
Publicado: (2020)

Short- and Long-term Effects of Dialysate Calcium Concentrations on Mineral and Bone Metabolism in Hemodialysis Patients: The K4 Study
por: Sakoh, Teppei, et al.
Publicado: (2019)

A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab
por: McClung, M. R., et al.
Publicado: (2020)

Bone‐Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment
por: Chavassieux, Pascale, et al.
Publicado: (2019)

OR13-05 Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis
por: Feldman, Robert, et al.
Publicado: (2020)

Romosozumab, clinical trials, and real-world care of patients with osteoporosis
por: Lewiecki, E. Michael
Publicado: (2020)

Romosozumab: a novel bone anabolic treatment option for osteoporosis?
por: Kerschan-Schindl, Katharina
Publicado: (2019)

Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk
por: Lim, Sian Yik
Publicado: (2022)

Romosozumab efficacy and safety in European patients enrolled in the FRAME trial
por: Langdahl, Bente, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3h3uuj3008rb3pr6sngaljug2f